Vyvanse is a drug approved by the U.S. Food and Drug Administration (FDA) as treatment of attention deficit hyperactivity disorder (ADHD). This prodrug is actually a central nervous system stimulant with lisdexamfetamine dimesylate as the active ingredient. The goal of ADHD therapy with Vyvanse is to enhance the ADHD patient’s capacity to pay attention and focus on a stimulus (Shire US, Inc., 2008). The emergence of Vyvanse brought about new hope to the ADHD patients and their families.
Lisdexamfetamine dimesylate as an amphetamine is a CNS stimulant that belongs to the non-catecholamine sympathomimetics classification. The mode of action of Vyvanse which is a prodrug of dextroamphetamine is presynaptic neuron blockage of the norepinephrine and dopamine reuptake and the amplification of extraneuronal space discharge of these substances. In cases of ADHD though the true mechanism of Vyvanse action remains undiscovered up to now. Absorption of lisdexamfetamine dimesylate (Vyvanse®) in the gastrointestinal tract when taken per orem is fast. Then this drug is transformed into the active substance –dextroamphetamine which causes its stimulant effects (FDA).
The efficacy of Vyvanse to control the clinical signs of ADHD such as hyperactivity and lack of capacity to focus attention is supported by scientific studies. According to these studies, Vyvanse is capable of improving the condition of ADHD patients as early as after three weeks of therapy. The positive results of the scientific studies conducted on Vyvance in clinical trials are the reason for its wide acceptance in medical practitioners involved in the treatment of ADHD patients. This CNS stimulant is prescribed to children of ages 6 to 12 and to adults as well. The significant improvements of the condition of ADHD patients are not only observed in the clinical trials but in the clinical setting also. The intensive positive reviews of Vyvanse lead to its present status as the “fastest-growing ADHD medication” (“Medical News TODAY”).
Medical News TODAY. 2008 . “Once-Daily VYVANSE(R) Significantly Improved ADHD Symptoms In One Of The Largest Controlled Stimulant Trials In Adults With ADHD”. Retrieved December 5, 2006, from http://www.medicalnewstoday.com/articles/124573.php
Shire US, Inc. 2008. Vyvanse: For the treatment of ADHD. Retrieved December 5, 2008, from
U.S. Food and Drug Administration (FDA). 2008. VyvanseTM (lisdexamfetamine dimesylate) C- II Rx Only. Retrieved December 5, 2008 from